Aktienanalyse zu Xeris Biopharma Holdings Inc (XERS)XERSXeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xeris Biopharma (XERS) is a good buy right now due to its current price of $10.31 being significantly below the analyst price target of $14 to $16, indicating a potential upside of 36% to 55%. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue reaching $92.1 million, a 29% year-over-year increase, and a gross margin of 83.47%, which reflects efficient operations. However, a risk to consider is the recent net loss of $31 million in Q2 2026, which could impact investor sentiment.

4 analysts cover XERS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.67.